ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1606

Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences

Maria I. Danila1, Kelly Gavigan2, Esteban Rivera2, William Nowell2, Michael George3, Jeffrey Curtis4, Lisa Christopher-Stine5, Shubhasree Banerjee3, Peter Merkel3, Kalen Young6, Dianne Shaw6, Jennifer Gordon6 and Shilpa Venkatachalam2, 1University of Alabama at Birmingham, Birmingham, AL, 2Global Healthy Living Foundation, Upper Nyack, NY, 3University of Pennsylvania, Philadelphia, PA, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5Johns Hopkins University, Baltimore, MD, 6Vasculitis Foundation, Kansas City, MO

Meeting: ACR Convergence 2021

Keywords: Access to care, autoimmune diseases, COVID-19

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: The COVID-19 pandemic disrupted the delivery of medical care and resulted in a substantial uptake in telemedicine care for patients with chronic conditions, including autoimmune rheumatic diseases. The objective of this study was to assess perceptions and preferences about telemedicine among patients with autoimmune rheumatic diseases during the COVID-19 pandemic.

Methods: We conducted an online survey among members of ArthritisPower and Vasculitis Patient Powered Research Network online patient registries and members of the following patient organizations: Myositis Support and Understanding, Lupus and Allied Disease Association, American Bone Health, and International Foundation for Autoimmune & Autoinflammatory Arthritis. Attitudes about telemedicine (i.e., telemedicine acceptability) were evaluated using the validated telemedicine perception questionnaire (TMPQ). The TMPQ score (range 17 to 85) was calculated; higher scores show higher acceptability. Visit satisfaction was measured using the one question scale from the validated Agency for Healthcare Research and Quality Consumer Assessment of Healthcare Providers and Systems (CAHPS)® survey (0-10 scale, 0 represents worst possible visit, 10 represents best possible visit). T-tests and multivariable linear regression compared the satisfaction and TMPQ scores between respondents who reported participating in video and phone-only visits. Chi-square tests compared preferences for telemedicine visits for specific clinical scenarios between those who had telemedicine visit versus those who had not.

Results: Between June 18 and August 10, 2020, we received 819 responses. Participants had a mean (SD) age of 58.6 (11.6) years and were mostly white (n= 759, 92.7%) and female (n=702, 85.7%). Of 618 participants who said that telemedicine was available to them, 449 (72.7%) reported having a telemedicine visit, with 303 (67.5%) reporting at least one telemedicine video visit; the remainder had a phone-only visit (Table 1). On a 0-10 scale, the mean (standard deviation) visit satisfaction score for telemedicine visits was 7.3 (1.8) with 25.8% being very satisfied (score 9 or 10). The mean (SD) telemedicine acceptability as assessed by TMPQ score was 62.8 (10.7). Video visits and higher TMPQ score were associated with higher satisfaction (data not shown). Preference for a telemedicine visit varied substantially by reasons for the visit (Figure 1). Compared to those who had not yet had a telemedicine visit, patients who had experienced telemedicine were more likely to prefer telemedicine for routine visits (73.7% vs 44.3%, p< 0.001), reviewing test results (64.8% vs 53.8%, p< 0.001), when considering changing medications (40.5% vs. 26.8%; p< 0.001), and when starting a new injectable medication (18.9% vs. 12.7%; p=0.02) (Table 2).

Conclusion: During the COVID-19 pandemic, patients with autoimmune rheumatic diseases frequently had telemedicine visits, the majority via video, and were often satisfied with these visits. These results suggest that because such patients prefer telemedicine for certain types of visits, maximizing effective use of telemedicine should take into consideration specific clinical scenarios and patient preferences.

Table 1

Figure 1

Table 2


Disclosures: M. Danila, Pfizer, 5, Pfizer, 11, AbbVie, 1, Amgen, 5, Amgen, 1, Boehringer Ingelheim, 5, Horizon, 5, WebMD, 12, writer, Novartis, 1; K. Gavigan, Global Healthy Living Foundation, 3; E. Rivera, None; W. Nowell, Global Healthy Living Foundation, 3, AbbVie, 5, Amgen, 5, Eli Lilly, 5; M. George, None; J. Curtis, AbbVie, 2, Amgen, 2, 5, Bristol-Myers Squibb, 2, Janssen, 2, Eli Lilly, 2, Myriad, 2, Pfizer Inc, 2, 5, Roche/Genentech, 2, UCB, 2, CorEvitas, 2, 5, Crescendo Bio, 5; L. Christopher-Stine, None; S. Banerjee, None; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9; K. Young, None; D. Shaw, None; J. Gordon, Excision Biotherapeutics, 2, 11; S. Venkatachalam, None.

To cite this abstract in AMA style:

Danila M, Gavigan K, Rivera E, Nowell W, George M, Curtis J, Christopher-Stine L, Banerjee S, Merkel P, Young K, Shaw D, Gordon J, Venkatachalam S. Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/telemedicine-for-rheumatology-care-during-the-covid-19-pandemic-patient-perceptions-and-preferences/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/telemedicine-for-rheumatology-care-during-the-covid-19-pandemic-patient-perceptions-and-preferences/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology